OliX Takes Aim at $60 Trillion Global Market With RNAi-Based Treatment for Macular Degeneration

South Korean biotech venture OliX has formally entered the global drug development race by submitting a Phase 2a trial plan for its age-related macular degeneration candidate OLX10212 to Australian regulators. Unlike existing drugs, which only slow lesion progression, the candidate has shown potential to improve vision, raising interest in whether it can reshape the geographic atrophy treatment market, which is growing to an annual value of 60 trillion won.

Limitations of Existing Treatments and OLX10212’s Differentiation

OliX announced on the 16th that it had submitted a Phase 2a plan to Bellberry HREC to evaluate the efficacy and safety of OLX10212 in patients with age-related macular degeneration accompanied by bilateral geographic atrophy (GA). Geographic atrophy is a disease that causes irreversible vision loss as retinal pigment epithelial cells are gradually lost, and it represents an area of substantial unmet medical need worldwide.

GA treatments currently approved in global markets only slow lesion progression and have limited ability to produce meaningful vision improvement. The risk of adverse events, including retinal vasculitis and intraocular inflammation caused by frequent intraocular injections, also remains unresolved. “There remains a substantial unmet medical need because safety issues have been reported with currently approved GA treatments, including intraocular inflammation associated with repeated dosing and an increased risk of choroidal neovascularization,” said Lee Dong-gi, CEO of OliX.

OLX10212 is based on OliX’s proprietary RNA interference (RNAi) platform for ophthalmic diseases, OASIS-Eye. Whereas existing treatments primarily inhibit vascular endothelial growth factor (VEGF), the candidate works by directly suppressing expression of the MyD88 gene, an upstream pathway that causes retinal pigment epithelial cell damage and inflammation. In an earlier Phase 1 trial conducted in the United States, the candidate demonstrated favorable safety and maintained vision improvement for up to 5 months after administration, drawing interest from the global pharmaceutical industry.

Global Data Collection Through a Multinational Trial in Four Countries

The trial was designed as a multicenter, randomized, sham-controlled study. A total of 64 participants will be divided into a treatment group and a sham-procedure control group. Participants in the treatment group will receive three intravitreal injections, administered once every 2 months, while the control group will receive placebo treatment on the same schedule. The total study period, including treatment and monitoring, will be 48 weeks and is expected to take approximately 38 months from approval. In particular, the study will assess inhibition of damage progression in the retinal ellipsoid zone at week 24 as a key endpoint.

The trial will be conducted in four countries—Australia, New Zealand, the United States and South Korea—and at up to six sites in Australia. The company added that the countries and sites involved may be adjusted according to its development strategy. South Korea’s inclusion in the global clinical trial network also demonstrates the competitiveness of the country’s clinical research infrastructure.

OliX is also accelerating efforts to build global clinical capabilities. In August 2026, the company recruited Min Ji-young, PhD, who led nucleic acid drug development for 20 years at global biopharmaceutical company GSK and the National Institutes of Health (NIH), as chief development officer (CDO). The move is viewed as a step toward developing clinical data packaging and strategies that meet the standards required by global regulatory agencies.

Targeting the 60 Trillion Won Market and Potential for Technology Licensing

According to a report released in August 2026 by global market research firm DataM Intelligence, the global GA treatment market is projected to grow at an average annual rate of 7.2% from $22.7 billion (approximately 30 trillion won) in 2025 to $44.59 billion (approximately 59 trillion won) in 2035. North America accounts for the largest share, at 44.6%, suggesting that OliX’s multinational trial strategy, including the United States, is aimed directly at a key market.

If the Phase 2a trial produces meaningful data on vision improvement and inhibition of retinal damage, OLX10212 could establish itself as a next-generation RNAi drug capable of replacing existing treatments. This could significantly expand opportunities for a large-scale technology export deal with a multinational pharmaceutical company or a global rights partnership. However, as OliX itself has stated, the statistical probability that a clinical trial drug will ultimately receive approval remains approximately 10%, so the possibility of results falling short of expectations during clinical development and the approval process must also be considered.